TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.0% ·
share flow +7.1% ·
net new positions 0.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.17M | $68.91M | n/a | n/a |
| Q2 2026 | 114 | +17 | 68.21M | $3.64B | +21 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.10M | -0.8% | $193.60M | 0.0% | ▼ Trim | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 6.61M | +10.3% | $158.06M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | Adage Capital Partners ✦ | 3.55M | +27.6% | $84.89M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 3.22M | -7.6% | $76.91M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 2.89M | +171.1% | $69.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 6 | Geode Capital Management ✦ (passive) | 2.14M | +6.7% | $51.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 1.75M | -29.8% | $41.88M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 1.27M | n/a | $30.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Wellington Management ✦ | 1.20M | +3331.9% | $28.72M | 0.0% | ▲ Add | 4 | SEC ↗ ×7 |
| 10 | Morgan Stanley ✦ | 1.12M | n/a | $26.70M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | JPMorgan Chase ✦ | 987.68K | n/a | $23.61M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 12 | Two Sigma Investments ✦ | 929.00K | +1.1% | $22.20M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 663.25K | -41.3% | $15.85M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Marshall Wace ✦ | 590.05K | -20.6% | $14.10M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Arrowstreet Capital ✦ | 328.65K | New | $7.85M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 313.38K | +37.4% | $7.49M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 17 | Millennium Management ✦ | 133.87K | -36.0% | $3.20M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 79.44K | +11.3% | $1.90M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 59.75K | -91.6% | $1.43M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | Fisher Asset Management ✦ | 39.34K | -8.9% | $940,249 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 27.74K | New | $663,058 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $7.85M | 0.0% |
| Gotham Asset Management | $663,058 | 0.0% |
Exited
| Point72 Asset Management | $2.48M | was 0.0% |
| Norges Bank | $1.05M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 121.20K shares, $3,600 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 78.40K sh · $4.31M
Officer, Director · 37.27K sh · $2.02M
Officer, Director · 128.06K sh · $6.78M
Officer · 8.28K sh · $538,917
Officer, Director · 101.69K sh · $6.57M
Officer, Director · 6.80K sh · $441,795
Officer, Director · 99.72K sh · $6.31M
Officer · 79.11K sh · $5.04M
Officer · 93.60K sh · $5.92M
Officer, Director · 96.12K sh · $6.12M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology